Effectiveness of electro‐acupuncture for cognitive improvement on Alzheimer's disease quantified via PET imaging of sphingosine‐1‐phosphate receptor 1
Authors: Wang Lu , Bi Lei , Qiu Yifan , Huang Guolong , Ye Peizhen , Liu Yongshan , Li An , Yang Xuan , Shen Peining , Wang Junfeng , Zeng Qi , Zhang Hongyu , Li Shengqiao , Jin Hongjun 
Published: September 2024

INTRODUCTION

Electro‐acupuncture (EA) has demonstrated potential in improving mild‐to‐moderate dementia in clinics, but the underlying scientific target remains unclear.

METHODS

EA was administered to APP/PS1 Alzheimer's disease (AD) mice, with untreated AD, and wild type (WT) mice serving as controls. The efficacy of EA was assessed by the Morris water maze cognitive functional tests. Brain magnetic resonance imaging–positron emission tomography (PET) scans using [18F]TZ4877 targeting sphingosine‐1‐phosphate receptor 1 (S1PR1) and [18F]AV45 targeting amyloid beta fibrils were conducted. The correlation between regional brain PET quantifications and cognitive functions was analyzed.

RESULTS

EA significantly improved cognitive and memory functions of AD (p  = 0.04) and reduced the uptake of [18F]TZ4877 in the cortex (p  = 0.02) and hippocampus (p  = 0.03). Immunofluorescence confirmed colocalizations of S1PR1 with glial fibrillary acidic protein and ionized calcium‐binding adaptor molecule‐1. Furthermore, immunohistochemistry showed a significant reduction of interleukin 1β and tumor necrosis factor α after EA treatment.

DISCUSSION

EA may reverse AD by suppressing neuroinflammation, and the PET imaging of S1PR1 seemed potent in evaluating the treatment for AD patients

Highlights

Electro‐acupuncture (EA) was administered to APP/PS1 Alzheimer's disease (AD) mice, with untreated AD, and wild type (WT) mice serving as controls. The efficacy of EA was assessed by the Morris water maze cognitive functional tests and positron emission tomography (PET) imaging quantifications.

PET tracer [18F]AV45 was used to detect amyloid beta deposition. An increased uptake of [18F]AV45 was found in AD compared to WT mice, with significance observed only in the cortex and not in the hippocampus. EA treatment exhibited a trend toward reduced [18F]AV45 uptake in AD mouse brains post‐treatment. However, statistical difference was not attained in most brain regions.

EA “Baihui (DU20) and Sishencong (EX‐HN1)” significantly improved cognitive and memory functions of AD (p = 0.04). Brain magnetic resonance imaging p(MRI)–positron emission tomography (PET) quantifications revealed that significantly reduced the uptake of [18F]TZ4877 in the cortex (p = 0.02) and hippocampus (p = 0.03) after EA treatment.

The correlation between PET quantifications and cognitive functions was analyzed and the most notable correlations were found between escape latency (reaction cognitive and memory behavior) and volume distribution (VT) quantifications of [18F]TZ4877. VT quantifications of [18F]TZ4877 in key brain regions for cognitive and memory ability, such as the cortex and hippocampus, positively correlated with platform latency (cortex p < 0.01, r = 0.7102; hippocampus p < 0.01, r = 0.6891).

Immunofluorescence confirmed colocalizations of S1PR1 with glial fibrillary acidic protein and ionized calcium‐binding adaptor molecule‐1 in the AD brain. And the EA treatment significantly reduced the signals in the cortex and hippocampus.

Immunohistochemistry showed a significant reduction of interleukin 1β and tumor necrosis factor α after EA treatment. EA reversed AD by suppressing neuroinflammation in the cortex and hippocampus.

The S1PR1 targeting PET tracer [18F]TZ4877 showed promise in evaluating the pathological progression of AD in clinical settings.